KeypointsPost operative radiotherapy (PORT) is commonly used in advanced stage larynx cancer.Patients with T3 primary tumors, N0 nodal disease, glottic subsite did not derive survival benefit when treated with PORT.Patients with T4a primary, N1 nodal disease, supraglottic subsite derived survival benefit with PORT.INTRODUCTIONApproximately 13 000 patients are diagnosed with laryngeal cancer each year, and 85‐95% of these tumours are squamous cell carcinomas (SCCs). The majority of patients with laryngeal cancer present with advanced stage disease, most of which is locally advanced. Advanced stage laryngeal cancer has a poor prognosis, carrying a five‐year survival rate of 39%‐60% independent of treatment modality.Advanced stage laryngeal cancer can be treated with surgery with or without adjuvant therapy or primary chemoradiation with similar overall long‐term survival outcomes. However, recent literature suggests that primary surgery may be more effective than chemoradiotherapy for specific subgroups of patients, such as those with T4a or supraglottic primaries, or N0 nodal disease. The gold‐standard surgical management for locally advanced disease is total laryngectomy and neck dissection although some T3 laryngeal tumours can be effectively managed with partial laryngectomy. The high efficacy of surgery for laryngeal cancer may be explained by the wide surgical margins inherent to total laryngectomy and the anatomic
Clinical Otolaryngology – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera